BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

  June 2, 2025

   · 

  11 min read
• Press Releases

  Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

  June 2, 2025

   · 

  7 min read
• Press Releases

  Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

  June 2, 2025

   · 

  12 min read
• Press Releases

  Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

  June 2, 2025

   · 

  3 min read
• Press Releases

  Immunocore to present at the 2025 Jefferies Global Healthcare Conference

  June 2, 2025

   · 

  1 min read
• Press Releases

  Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

  June 2, 2025

   · 

  5 min read
• Press Releases

  KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)

  June 2, 2025

   · 

  19 min read
• Press Releases

  Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

  June 2, 2025

   · 

  10 min read
• Press Releases

  Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

  June 2, 2025

   · 

  9 min read
• Press Releases

  Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

  June 2, 2025

   · 

  14 min read